Answers are grounded in this paper and cite their sources.
Background To quantify the incremental value of pretreatment magnetic resonance imaging (MRI) measurements beyond clinicopathological variables for predicting Miller–Payne grade 5 (MP5) after neoadjuvant therapy (NAT), and to describe performance in a same-centre temporal cohort. Methods Patients receiving NAT were divided chronologically into development (n = 371)\(\:n=371\) and same-centre temporal (n = 93)\(\:n=93\) cohorts. Core clinicopathological, MRI-integrated, and Expanded predictor sets were evaluated with six algorithms using nested five-fold cross-validation repeated five times; hyperparameters were tuned within each outer training fold. After the unified development comparison, the MRI-integrated eXtreme Gradient Boosting (XGBoost) model was selected post hoc as a candidate for further study. Results Development MRI-integrated receiver operating characteristic areas under the curve (ROC-AUCs) ranged from 0.8447 to 0.8644 across the six algorithms. XGBoost had the highest five-repeat mean (0.8644), only 0.0002 above Random Forest (0.8642). Its Core-to-MRI ΔAUC was + 0.0124 (Bonferroni simultaneous bootstrap 95% CI for the six Core-to-MRI comparisons, − 0.0036 to + 0.0289; separately, Holm-adjusted P = 0.221); all six adjusted intervals crossed zero. In the temporal cohort (43/93 MP5), XGBoost achieved ROC-AUC 0.8507 (95% CI, 0.7618–0.9222), compared with 0.8535 (0.7665–0.9239) for Random Forest. The post hoc paired AUC difference was − 0.0028 (XGBoost minus Random Forest; DeLong 95% CI, − 0.0194 to 0.0139; two-sided P = 0.743). XGBoost had a Brier score of 0.1632 (95% CI, 0.1314–0.1994), joint-fit calibration intercept of 0.093 (95% CI, − 0.427 to 0.634), and slope of 1.373 (95% CI, 0.888–2.395). Conclusions Clinicopathological variables provided good MP5 discrimination. Routine MRI measurements yielded small, uncertain incremental gains. XGBoost was selected after the unified development comparison. Its temporal discrimination and calibration estimates are exploratory results from already available data; independent validation of discrimination, calibration, and clinical utility is needed before clinical use.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: